European medicines agency recommends market approval of avt06, alvotech's proposed biosimilar to eylea® (aflibercept)

Reykjavik,  iceland and london, uk (june 23, 2025) — alvotech (nasdaq: alvo), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide and advanz pharma, a uk headquartered global pharmaceutical company with a strategic focus on specialty, hospital, and rare disease medicines in europe, today announced that the european medicines agency's (ema) committee for medicinal products for human use (chmp) adopted a positive opinion recommending approval for avt06, alvotech's proposed biosimilar to eylea® (aflibercept 2 mg). based on a positive recommendation by chmp, biosimilar medicines can be approved by the european commission for marketing in the european economic area, that includes the 27 member states of the european union, in addition to norway, iceland and lichtenstein.
ALVO Ratings Summary
ALVO Quant Ranking